Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
Status:
Enrolling by invitation
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib.
Subjects will visit the clinic every 4 week to assess the safety and efficacy of the
treatment, until Week 36. A final follow-up phone call is planned on Week 38.